Go generic for research
There’s now an innovative way for people living with the blood cancer, chronic myeloid leukaemia (CML) to support vitally needed medical research.
For Benefits Medicine (FBM) supports the Leukaemia Foundation through a partnership where 100% of profits from an generic drug called cipla imatinib will be invested into important blood cancer research.
This drug, used to treat chronic myeloid leukaemia (CML), is approved and meets the same strict quality and safety regulations applied to the original brand of imatinib regarding quality, safety and effectiveness.
“By going generic, people living with CML can make a significant contribution to our patient support and research. We encourage individuals to have considered discussion with their family and haematologist before making the switch,” said Leukaemia Foundation CEO, Bill Petch.
Find out how to make the switch at www.forbenefitmedicines.com.au
Developed by the Leukaemia Foundation in consultation with people living with a blood cancer, Leukaemia Foundation support staff, haematology nursing staff and/or Australian clinical haematologists. This content is provided for information purposes only and we urge you to always seek advice from a registered health care professional for diagnosis, treatment and answers to your medical questions, including the suitability of a particular therapy, service, product or treatment in your circumstances. The Leukaemia Foundation shall not bear any liability for any person relying on the materials contained on this website.